203 related articles for article (PubMed ID: 28247603)
41. Empagliflozin, a sodium glucose cotransporter-2 inhibitor, ameliorates peritoneal fibrosis via suppressing TGF-β/Smad signaling.
Shentu Y; Li Y; Xie S; Jiang H; Sun S; Lin R; Chen C; Bai Y; Zhang Y; Zheng C; Zhou Y
Int Immunopharmacol; 2021 Apr; 93():107374. PubMed ID: 33517222
[TBL] [Abstract][Full Text] [Related]
42. The monocyte chemoattractant protein-1 (MCP-1)/CCR2 system is involved in peritoneal dialysis-related epithelial-mesenchymal transition of peritoneal mesothelial cells.
Lee SH; Kang HY; Kim KS; Nam BY; Paeng J; Kim S; Li JJ; Park JT; Kim DK; Han SH; Yoo TH; Kang SW
Lab Invest; 2012 Dec; 92(12):1698-711. PubMed ID: 23007133
[TBL] [Abstract][Full Text] [Related]
43. Connective tissue growth factor and its regulation in the peritoneal cavity of peritoneal dialysis patients.
Zarrinkalam KH; Stanley JM; Gray J; Oliver N; Faull RJ
Kidney Int; 2003 Jul; 64(1):331-8. PubMed ID: 12787426
[TBL] [Abstract][Full Text] [Related]
44. Oral supplementation with sulodexide inhibits neo-angiogenesis in a rat model of peritoneal perfusion.
Pletinck A; Van Landschoot M; Steppan S; Laukens D; Passlick-Deetjen J; Vanholder R; Van Biesen W
Nephrol Dial Transplant; 2012 Feb; 27(2):548-56. PubMed ID: 21750165
[TBL] [Abstract][Full Text] [Related]
45. [The role of TGF-beta1/Smads in the development of peritoneal fibrosis induced by high glucose peritoneal dialysate and LPS].
Dou XR; Yu XQ; Li XY; Chen WF; Hao WK; Jia ZJ; Peng WX; Wang X; Yin PD; Wang WJ; Zheng ZH
Zhonghua Yi Xue Za Zhi; 2005 Sep; 85(37):2613-8. PubMed ID: 16321321
[TBL] [Abstract][Full Text] [Related]
46. Acquired Decline in Ultrafiltration in Peritoneal Dialysis: The Role of Glucose.
Krediet RT
J Am Soc Nephrol; 2021 Oct; 32(10):2408-2415. PubMed ID: 34321252
[TBL] [Abstract][Full Text] [Related]
47. Protective effects and mechanisms of omega-3 polyunsaturated fatty acid on intestinal injury and macrophage polarization in peritoneal dialysis rats.
Tang H; Zhu X; Gong C; Liu H; Liu F
Nephrology (Carlton); 2019 Oct; 24(10):1081-1089. PubMed ID: 30887626
[TBL] [Abstract][Full Text] [Related]
48. Paricalcitol ameliorates epithelial-to-mesenchymal transition in the peritoneal mesothelium.
Kang SH; Kim SO; Cho KH; Park JW; Yoon KW; Do JY
Nephron Exp Nephrol; 2014; 126(1):1-7. PubMed ID: 24458092
[TBL] [Abstract][Full Text] [Related]
49. Biocompatibility of peritoneal dialysis fluids: long-term exposure of nonuremic rats.
Musi B; Braide M; Carlsson O; Wieslander A; Albrektsson A; Ketteler M; Westenfeld R; Floege J; Rippe B
Perit Dial Int; 2004; 24(1):37-47. PubMed ID: 15104335
[TBL] [Abstract][Full Text] [Related]
50. Reduction of perlecan synthesis and induction of TGF-beta1 in human peritoneal mesothelial cells due to high dialysate glucose concentration: implication in peritoneal dialysis.
Yung S; Chen XR; Tsang RC; Zhang Q; Chan TM
J Am Soc Nephrol; 2004 May; 15(5):1178-88. PubMed ID: 15100358
[TBL] [Abstract][Full Text] [Related]
51. Inhibition of the effect of high glucose on the expression of Smad in human peritoneal mesothelial cells.
Yao Q; Qian JQ; Lin XH; Lindholm B
Int J Artif Organs; 2004 Oct; 27(10):828-34. PubMed ID: 15560676
[TBL] [Abstract][Full Text] [Related]
52. SGLT2 Inhibition by Intraperitoneal Dapagliflozin Mitigates Peritoneal Fibrosis and Ultrafiltration Failure in a Mouse Model of Chronic Peritoneal Exposure to High-Glucose Dialysate.
Balzer MS; Rong S; Nordlohne J; Zemtsovski JD; Schmidt S; Stapel B; Bartosova M; von Vietinghoff S; Haller H; Schmitt CP; Shushakova N
Biomolecules; 2020 Nov; 10(11):. PubMed ID: 33228017
[TBL] [Abstract][Full Text] [Related]
53. By reducing production of vascular endothelial growth factor octreotide improves the peritoneal vascular alterations induced by hypertonic peritoneal dialysis solution.
Günal AI; Celiker H; Akpolat N; Ustündag B; Duman S; Akcicek F
Perit Dial Int; 2002; 22(3):301-6. PubMed ID: 12227386
[TBL] [Abstract][Full Text] [Related]
54. Inflammation, neoangiogenesis and fibrosis in peritoneal dialysis.
de Lima SM; Otoni A; Sabino Ade P; Dusse LM; Gomes KB; Pinto SW; Marinho MA; Rios DR
Clin Chim Acta; 2013 Jun; 421():46-50. PubMed ID: 23466603
[TBL] [Abstract][Full Text] [Related]
55. Peritoneal inflammation and fibrosis in C-reactive protein transgenic mice undergoing peritoneal dialysis solution treatment.
Poon PY; Lan HY; Kwan BC; Huang XR; Chow KM; Szeto CC; Li PK
Nephrology (Carlton); 2017 Feb; 22(2):125-132. PubMed ID: 26857687
[TBL] [Abstract][Full Text] [Related]
56. MicroRNA-21 promotes the progression of peritoneal fibrosis through the activation of the TGF-β/Smad signaling pathway: An in vitro and in vivo study.
Ma YL; Chen F; Yang SX; Chen BP; Shi J
Int J Mol Med; 2018 Feb; 41(2):1030-1038. PubMed ID: 29207016
[TBL] [Abstract][Full Text] [Related]
57. miR-15a-5p suppresses peritoneal fibrosis induced by peritoneal dialysis via targeting VEGF in rats.
He Q; Wen L; Wang L; Zhang Y; Yu W; Zhang F; Zhang W; Xiao J; Wen X; Zhao Z
Ren Fail; 2020 Nov; 42(1):932-943. PubMed ID: 32909490
[TBL] [Abstract][Full Text] [Related]
58. Parthenolide, an NF-κB inhibitor, alleviates peritoneal fibrosis by suppressing the TGF-β/Smad pathway.
Zhang Y; Huang Q; Chen Y; Peng X; Wang Y; Li S; Wu J; Luo C; Gong W; Yin B; Xiao J; Zhou W; Peng F; Long H
Int Immunopharmacol; 2020 Jan; 78():106064. PubMed ID: 31838448
[TBL] [Abstract][Full Text] [Related]
59. Acute effects of peritoneal dialysis solutions in the mesenteric microcirculation.
Frajewicki V; Brod V; Kushnir D; Kohan R; Bitterman H
Transl Res; 2009 May; 153(5):249-56. PubMed ID: 19375686
[TBL] [Abstract][Full Text] [Related]
60. Genetic or pharmacologic blockade of enhancer of zeste homolog 2 inhibits the progression of peritoneal fibrosis.
Shi Y; Tao M; Wang Y; Zang X; Ma X; Qiu A; Zhuang S; Liu N
J Pathol; 2020 Jan; 250(1):79-94. PubMed ID: 31579944
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
